71 results about "Dextran sulphate" patented technology

The invention relates to novel absorbable polyesters, produced by ring-opening polymerisation of hydroxycarboxylic acids in the presence of a polyol containing an electrolyte, in an extruder. In particular, the invention relates to novel polylactide glycolide polyesters which are essentially free of dextran sulphate and which are produced by ring-opening polymerisation of lactide and glycolide in the presence of dextran sulphate in the extruder; to the production of the same and to their use in depot medicaments.

The invention discloses a model for protecting mouse ulcerative colitis by antibacterial peptide C-BF. Cathelicin-BF has broad-spectrum antibacterial activity, especially for Gram negative bacteria. Inflammatory bowel diseases (IBDs) comprise ulcerative colitis (UC) and Crohn disease (CD), and pathomechanisms of the diseases are not clear yet. A model for inducing the mouse ulcerative colitis by 3% dextran sulphate sodium (DSS) is built; a PBS solution of the C-BF is subjected to rectal injection once per day, the dose of the C-BF is 5mg/kg, the continuous injection time is one week, a mouse is weighed and the body weight data of the mouse is recorded each day during experimental period, and the rectal bleeding and dung forming situations of the mouse are observed. The model is used for making a research on a protection effect on the mouse UC caused by the C-BF.

The invention discloses a Chinese hamster ovary culture medium as well as a preparation method and application thereof. The culture medium comprises ascorbic acid, pyridoxine hydrochloride, vitamin B12, nicotinamide, riboflavin, thiamine chloride, choline chloride, folic acid, calcium pantothenate, sodium pyruvate, reduced glutathione, inositol, biotin, hypoxanthine, putrescine, lipoic acid, linoleic acid, thymine, glucose, HEPES (2-hydroxyethyl) buffer solution, dextran sulphate, Pluronic-F68, various amino acids and salts thereof and various inorganic salts. The culture medium has low cost, and the component does not contain animal origin ingredients, does not contain protein and has definite chemical ingredients. All ingredients are cooperated and blended, and the Chinese hamster ovary culture medium can satisfy the basic growth requirement of cells, and can effectively regulate, transfer and control the culture of cells so as to realize good high-density cell culture. Compared with the culture effect of the existing culture medium, the culture effect of culture medium disclosed in the invention is at least equivalent to even superior to the existing culture medium.

The invention discloses novel application of dextran sulfate in preparing a medicament for treating hepatic fibrosis. The medicament can be used for inhibiting inflammatory reaction in hepatic fibrosis attaching process, so that attack or symptom worsening of hepatic fibrosis can be inhibited. Dextran sulfate has good curative effect in a carbon tetrachloride induced animal model; and the medicaments used in the application can be easily acquired, low in price and stable in properties, are convenient to store and transport, and have wide application prospect.

The invention discloses a BMP-2 (Bone Morphogenetic Protein-2) sustained release microsphere and a preparation method thereof. The preparation method of the BMP-2 sustained release microsphere comprises the following steps of: dissolving chitosan in an aqueous solvent so as to obtain a chitosan solution; dissolving BMP-2 into a dextran sulfate sodium aqueous solution, dropwise adding the chitosan solution into the dextran sulfate sodium aqueous solution under the condition of stirring, then adding a metal salt so as to form the microsphere in a reaction solution, washing and freeze-drying so as to obtain the BMP-2 sustained release microsphere. The matrix component of the microsphere prepared by using the method comprises chitosan and dextran sulfate sodium, the wrapped medicine is BMP-2, the average particle size of the microsphere is 200-900nm, the encapsulation efficiency can be 75-90%, and the BMP-2 is long in protein activity duration and sustained release period. The BMP-2 sustained release microsphere is simple in preparation process, low in production cost, easy to carry out, and mild in reaction condition, and does not need the addition of reagents which can influence the protein activity of BMP-2; and the e microsphere is round and complete in appearance, good in polydispersity, non-sticky after being freeze-dried and soluble in water.

The invention provides a method for building a dextran sodium sulphate induced enteritis mouse model. The method includes the following steps: A, choosing female C57BL/6 mice with the weight of 19-21g as the objects to build the mouse model; B, dissolving dextran sulphate sodium salt solution in disinfected drinking water to prepare dextran sulphate sodium salt solution with the weight percentage concentration of 2%, and placing the solution in a water bottle for protecting away from the sun, wherein the solution is prepared when required; C, feeding the chosen C57BL/6 mice in a storageprotect feature (SPF) level animal house, enabling the mice to drink the dextran sulphate sodium salt solution prepared in the step B for six days and then drink the normal drinking water for four days. Accordingly, the chosen C57BL/6 mice are dextran sodium sulphate induced enteritis mouse models. By means of the method for building the dextran sodium sulphate induced enteritis mouse model, death rate of animals is reduced to be zero, and pathology expressions are the same, so that the model is stable, reliable and repeatable.

Infective aggregating forms of proteins such as PrP, amyloid, and tau are bound selectively in the presence of the normal form protein using a polyionic binding agent such as dextran sulphate or pentosan (anionic), or polyamine compounds such as pDADMAC (cationic) under selective binding conditions including the use of n-lauroylsarcosine at mildly alkaline pH, and may then be assayed.

The invention relates to recombinant human lactoferrin (rhLF) silkworm chrysalis powder as well as a preparation method and application thereof and belongs to the technical field of biological medicines. A recombinant virus is constructed mainly by adopting a silkworm chrysalis baculovirus expression system, the rhLF is expressed with a silkworm chrysalis serving as a bioreactor, the silkworm chrysalis diseased after being inoculated with the recombinant virus is prepared into freeze-dried powder, the activity of the freeze-dried powder is detected by performing antibacterial experiments in vitro, and the freeze-dried powder is poured into the stomach of a mouse to treat the dextran sulphate sodium (DSS) induced ulcerative colitis of the mouse. The analysis on the disease activity index (DAI) of the mouse and the detection on the content of myeloperoxidase (MPO) in the colonic tissue of the mouse show that the rhLF with antibacterial activity is expressed successfully in the silkworm chrysalis, and the rhLF silkworm chrysalis powder has a certain effect of treating the DSS induced ulcerative colitis of the mouse. The preparation method provided by the invention is simple, is low in cost and is used for preparing a novel oral protein medicine.

The invention relates to an adsorbent for extracorporeal blood circulation to remove LDL, a preparation method thereof, and a perfusion device. The adsorbent is formed by introducing an amino group toa carrier and reacting the amino group with a polyanion; and the polyanion is at least one of polyacrylic acid, carbomer and dextran sulfate, wherein the polyacrylic acid is a polyacrylic acid havinga molecular weight of 5,000 to 450,000, or the polyacrylic acid is a mixture of at least two polyacrylic acids with different molecular weights; the carbomer is carbomer with a single grade, or the carbomer is a mixture of at least two carbomers with different grades; and the dextran sulfate is subjected to an hydroformylation reaction together with periodate prior before reacting with the aminogroup, and is subjected to a reduction reaction after reacting with the amino group. The adsorbent has a high adsorption rate and specific adsorption to the LDL.

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

The invention belongs to the technical field of medicines, and particularly relates to a salvianic acid A sodium oral self-assembled liposome for treating ulcerative colitis and a preparation method thereof. The salvianic acid A sodium oral self-assembled liposome for treating ulcerative colitis prepared by the method disclosed by the invention is prepared by taking salvianic acid A sodium, phospholipid, cholesterol, chitosan and sodium alginate as raw materials and adopting a reversed-phase evaporation method and an LbL self-assembly technology. A mouse experiment of the DSS (dextran sulfate sodium) induced ulcerative colitis proves that the oral salvianic acid A sodium self-assembled liposome prepared by the invention has the effects of improving clinical symptoms of mice with colitis, reducing the content of proinflammatory factors TNF-alpha, IF-6 and IF-1beta in serum of the mice with ulcerative colitis, increasing the content of anti-inflammatory factor IL-10 and alleviating intestinal flora imbalance of mice with ulcerative colitis, thereby having a relatively good medicine effect on treating ulcerative colitis.

The invention provides application of caffeic acid 3,4-dyhydroxy phenethyl ester (CADPE) to preparing a medicine for preventing colorectal cancer. The medicine is prepared from CADPE as an active component and a pharmaceutically acceptable carrier. The CAPDE is capable of effectively preventing early-stage occurrence of ICR (Institute for Cancer Research) mouse colorectal cancer induced by 1,2-dimethylhydrazine (DMH) and dextran sulphate sodium salt, has no conspicuous toxicity, and has the function mechanisms of inhibiting inflammatory cell invasion and infiltration and inhibiting NF-KappaB expression in monocyte, inhibiting expression of beta-catenin in aberrant crypt, reducing expression of cell proliferin PCNA and Cyclin D1, an anti-apoptoasis protein surviving and a cancer gene c-Myc,and inhibiting tumor vessel proliferation. Novel treatment means are provided for clinical prevention and treatment on colorectal cancer.

The invention discloses application of folium perillae extracts in preparation of a medicine for treating and/or preventing the inflammatory bowel disease. The folium perillae extracts disclosed by the invention have a reverse effect on diarrhea, hematochezia, weight loss and the colon position pathological injuries of a mouse with inflammatory bowel disease induced by low molecular weight dextransulfate, can obviously inhibit secretion of model mouse colon tissue cell factors NO, IFN-gamma, IL-4, IL-10 and IL-17, and can obviously inhibit the intestinal tissue MPO level of the model mouse.

The invention discloses application of a nostoc commune vauch alcohol extract to preparation of medicines for treating an inflammatory bowel disease. A preparation method of the nostoc commune vauch alcohol extract comprises the following steps: taking nostoc commune vauch, using low-carbon alcohol as a solvent, extracting under a heating condition, collecting an extract, recycling the solvent toobtain the nostoc commune vauch alcohol extract. Through experiments, the applicant finds that the nostoc commune vauch alcohol extract significantly improves the weight loss of a DSS (dextran sulphate sodium)-induced UC (ulcerative colitis) model mouse, inhibits DAI (disease activity index) score increase, relieves UC-induced mouse colon length reduction and reduces inflammatory cell infiltrationand tissue damage; in addition, the nostoc commune vauch alcohol extract significantly reduces the contents of colon tissue cytokines TNF-alpha and IL-6, and such effect is closely related to activation of a key transcription factor NF-kappaB inhibiting inflammatory signaling pathways. Experimental results of the applicant show that the nostoc commune vauch alcohol extract can be used for treating the inflammatory bowel disease, relieving an inflammatory reaction of the DSS-induced UC model and improving the UC severity.

The invention belongs to the technical field of medicines, and discloses pomegranate rind tannin and application of punicalagin and granatin serving as effective components of the pomegranate rind tannin in preparation of medicines for treating ulcerative colitis. After the pomegranate rind tannin is used for treating mouse ulcerative colitis induced by dextran sulfate sodium salt, the body weight, the disease activity index, the colorectum length, the colorectum mucous membrane form and the goblet cell number are improved to a certain extent compared with a model group; therefore, the pomegranate rind tannin has a certain treatment effect on ulcerative colitis. The effective components punicalagin and granatin in the pomegranate rind tannin are independently or jointly administered, so that the pomegranate rind tannin has a very good effect on ulcerative colitis, and drug combination is optimal.

The invention discloses a filling liquid for stabilizing adsorption performance of an adsorbent and application thereof. The filling liquid comprises a stabilizer and a base liquid, wherein the stabilizer is one or more of dextran and derivatives thereof, and the mass volume ratio of the stabilizer to the base liquid is 0.02-2.5g: 100 ml. The filling liquid provided by the invention can obviouslyreduce the reduction rate of the adsorption performance of the adsorbent after high-pressure steam sterilization, and is suitable for various adsorbents, especially low density lipoprotein adsorbentswith dextran sulfate as a ligand.

The invention discloses a sample pretreatment solution for quantitative vitamin D detection. The solution comprises normal saline, dextran sulfate sodium salt and a beta-isotropism blocking agent. Thedextran sulfate sodium salt and the beta-isotropism blocking agent can be used to fully separate 25-hydroxyvitamin D to be analyzed from binding protein to a certain extent. Non-specific interferenceeffect in a serum matrix is reduced, the sample can be well separated in the further separation and purification process, a high-quality to-be-analyzed object can be obtained from the treated sample,and the quantitative detection accuracy of the vitamin D is improved.

The invention relates to the technical field of in-vitro diagnosis, in particular to a sample diluent, a preparation method thereof and an immunoassay method for eliminating abnormal detection of a fresh sample. The sample diluent comprises a component A, a component B and a biological buffer solution; the component A is lipoic acid or dihydrolipoic acid; and the component B is dextran sulfate or a salt thereof. According to the invention, the lipoic acid and the dextran sulfate are combined and applied to immune clinical detection, so that the abnormality of detection results caused by different freshness degrees of samples is avoided. The diluent can effectively prevent interference in a fresh sample, and can eliminate complement, fibrin and other main interfering substances contained in the sample. The diluent can reduce non-specific reaction in immunoassay, so that the accuracy and precision of a reagent are improved. The diluent is simple in preparation method, and has safety and environmental friendliness.